The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Regeneron Announces Upcoming 2013 Investor Conference Presentations

Tuesday, February 19, 2013

Regeneron Announces Upcoming 2013 Investor Conference Presentations09:30 EST Tuesday, February 19, 2013TARRYTOWN, N.Y., Feb. 19, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:Citi 2013 Global Healthcare Conference; Dyslipidemia Panel on Tuesday, February 26, 2013.  The session is scheduled for 1:30 p.m. Eastern Time. RBC Capital Markets' 2013 Global Healthcare Conference on Wednesday, February 27, 2013.  The presentation is scheduled for 9:30 a.m. Eastern Time. Barclays Global Healthcare Conference on Tuesday, March 12, 2013.  The presentation is scheduled for 2:30 p.m. Eastern Time.The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentations will be available for 30 days.About Regeneron Pharmaceuticals, Inc.Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma.  For additional information about the company, please visit www.regeneron.com.Contact Information: Michael Aberman, M.D. Peter DworkinInvestor Relations Corporate Communications                          914.847.7799 914.847.7640             michael.aberman@regeneron.competer.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.